Biotech

The Latest On CAR-T: Good and Bad

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 18/09/2026, 20:46:48 UTC.

Briefings

This briefing summarizes recent developments in CAR-T cell therapies, highlighting allogenic approaches for lymphoma and renal carcinoma that achieved a 31% objective response rate in heavily pre-treated patients. It notes mixed results in autoimmune trials, including Kyverna's approval pursuit for stiff person syndrome, while contrasting this with recent Chinese research using lentiviruses to achieve B cell resets in neurological autoimmune disease. The text also addresses immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome as a major toxicity concern and mentions two large pharma projects halted due to toxicity issues.

Key points

• Allogenic CAR-T therapy for lymphoma and renal carcinoma showed a 31% objective response rate in a heavily pre-treated population, with the company Allogene receiving FDA designation for Regenerative Medicine Advanced Therapy.
• Recent Chinese research utilized lentiviruses to induce B cell resets in patients with neurological autoimmune disease, demonstrating clinical improvements at six months post-infusion.

Context and limitations

Data reflects a single snapshot from September 2026 regarding specific trials and reports; preprint status and long-term follow-up data for the Chinese study remain unverified.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 19/09/2026, 15:44:28 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeig24bfp725dihkj3nb4cnulwapmfxocbi7bihuzfjnc5mwuwfcvye